DRG Market Assessment reports

Episodic and chronic migraines are often disabling and reduce patients’ quality of life. Despite triptans’ dominance in the treatment algorithm, many patients respond inadequately, cannot…

Preventive migraine care in the United States continues to evolve. Since 2018, CGRPtargeting mAbs (Aimovig, Emgality, Ajovy, Vyepti) and oral gepants (Nurtec ODT, Qulipta) have become established…

Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…

Since 2018, the U.S. treatment landscape for migraine prophylaxis has undergone a major expansion with the entry of the novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies…

Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…

Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…